In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

NEW YORK – Researchers are planning larger follow-up studies of AstraZeneca's Lynparza (olaparib) in biomarker-selected subgroups after a Phase II trial showed the PARP inhibitor was effective in ...

Lymphedema is tissue swelling caused by an accumulation of protein-rich fluid that’s usually drained through the body’s lymphatic system. Credit: JulieK2 via Shutterstock. Koya Medical has shared data ...

The new medication is a targeted therapy for people with BRCA1 and BRCA2 mutations called Lynparza which aims to stop recurrence. Being done with chemo and radiation marks the end of chapter one.

1. U.S. Food and Drug Administration approves FoundationOne CDx and FoundationOneLiquid CDx as companion diagnostics for Lynparza (olaparib) in combination with abiraterone for patients with ...

According to GlobalData, there are three currently available mpox vaccines from Bavarian Nordic, KM Biologics, and Emergent BioSolutions. Credit: MargJohnsonVA via Shutterstock. In response to the ...

In particular, the company's launched cancer drugs Tagrisso, Imfinzi, Lynparza, and Calquence are well positioned based on leading efficacy in hard-to-treat cancers. These drugs also carry strong ...

In March, the company reported that a late-stage study evaluating the combination of Keytruda and Lynparza in metastatic non-squamous NSCLC indication failed to meet its primary endpoints.

In recent months, the Keytruda-Astraeneca Lynparza combination and Keytruda with Eisai's Lenvima also failed separate trials as cancer treatments. Keytruda belongs to a class of medicines called ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.